December 2024 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Deucravacitinib helped a man regrow hair significantly.
3 citations
,
February 2022 in “Rheumatology” Baricitinib was effective in treating a patient with dermatomyositis and hair loss.
16 citations
,
April 2014 in “Expert Opinion on Pharmacotherapy” Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.
14 citations
,
January 2017 in “Dermatology Online Journal” Adalimumab can cause hair loss and scalp issues in some psoriasis patients.
2 citations
,
March 2025 in “International Journal of Dermatology” Tralokinumab successfully treated alopecia areata in a patient with atopic dermatitis.
August 2024 in “JAAD Case Reports” Upadacitinib successfully regrew hair in a child with alopecia universalis and specific genetic mutations.
July 2024 in “Journal of Investigative Dermatology” Biosimilars lower costs but don't significantly improve access.
4 citations
,
January 2018 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Panitumumab can cause excessive ear hair growth.
March 2024 in “Poster presentations” Anifrolumab improves quality of life and reduces steroid use in SLE patients.
4 citations
,
September 2024 in “BMC Cancer” Adding dutasteride to therapy may improve treatment for advanced salivary duct cancer.
Anifrolumab treatment improves quality of life and reduces disease activity and steroid use in SLE patients.
November 2024 in “Journal of Investigative Dermatology” Tildrakizumab significantly improved psoriasis symptoms and well-being over 52 weeks.
10 citations
,
August 2019 in “European Journal of Dermatology” The document did not conclude on apremilast's effectiveness for severe alopecia areata.
36 citations
,
June 2014 in “Experimental Neurology” Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.
1 citations
,
September 2022 Distinguishing drug-induced lupus from systemic lupus is challenging and requires careful monitoring.
December 2020 in “Dermatología argentina” A patient got a skin reaction on their hands and feet after using secukinumab for psoriasis.
1 citations
,
May 2025 in “BMC Cancer” CDK4/6 inhibitors affect safety and quality of life differently, requiring careful use.
March 2026 in “Preprints.org” Plerixafor may help treat pigmentation disorders by promoting skin repigmentation.
7 citations
,
November 2021 in “JAAD Case Reports” Mogamulizumab can cause hair loss and skin rashes.
6 citations
,
February 2023 in “Journal of the American Academy of Dermatology” Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.
10 citations
,
January 2023 in “SAGE Open Medical Case Reports” Upadacitinib may effectively treat both alopecia universalis and Crohn's disease.
39 citations
,
March 2007 in “Journal of Cosmetic Dermatology” Dutasteride helps slow hair loss and boosts hair growth.
9 citations
,
March 2008 in “British Journal of Dermatology” Efalizumab can cause unexpected excessive hair growth.
August 2009 in “Australian Prescriber” Eculizumab helps reduce blood transfusions and stabilize hemoglobin but increases infection risk and is expensive.
June 2024 in “Journal of Clinical Oncology” Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Psoriasis patients on biologic therapy have a weaker immune response to COVID-19 vaccination than healthy people.
July 2025 in “Journal of Investigative Dermatology” Upadacitinib effectively treats pyoderma gangrenosum.
13 citations
,
June 2023 in “Frontiers in Pharmacology” Trastuzumab deruxtecan is effective for advanced breast cancer but has side effects like nausea and fatigue.
2 citations
,
February 2025 in “Allergies” Lanadelumab greatly reduces hospital visits and angioedema episodes, improving life quality for hereditary angioedema patients.